MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53À/À cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wildtype E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73a and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1-dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.
Introduction
The human homolog of the mouse double minute (MDM2) is an oncogene overexpressed in different types of malignancies, including solid tumors, sarcomas and leukemias (Momand et al., 1998) . MDM2 plays a central role in cancer development and progression, mainly by antagonizing the p53 tumor suppressor activity. Binding of MDM2 to p53 inhibits its transcriptional activity and targets p53 for ubiquitin-dependent proteolysis (Midgley and Lane, 1997; Piette et al., 1997) . In response to cellular stress, the ability of MDM2 to bind p53 is blocked or altered in a manner that prevents MDM2-mediated degradation. As a result, p53 levels rise, causing cell cycle arrest or apoptosis. The mdm2 gene is itself transcriptionally activated by p53 in a regulatory feedback loop (Bond et al., 2005) . Several strategies have been explored to disrupt the p53-MDM2 interaction, including the use of small peptides (Wasylyk et al., 1999) , antisense oligonucleotides (Bianco et al., 2005) and inhibitors of MDM2 ubiquitin ligase .
The Nutlins are novel small-molecule inhibitors of MDM2, which activate the p53 pathway only in cells with wild-type but not mutant p53 (Vassilev et al., 2004) . These compounds bind in the p53-binding pocket of MDM2 and displace p53 from the complex. This results in p53 stabilization, p21 induction, cell cycle arrest in G1 and G2 phases, apoptosis and growth inhibition of human tumor xenografts in nude mice. Although MDM2 has been extensively characterized as a regulator of p53, there is considerable evidence that MDM2 functionally interacts with a number of other proteins, including the tumor suppressor p14ARF (Honda and Yasuda, 1999) , the retinoblastoma pRb (Xiao et al., 1995) , the ribosomal protein L5 (Dai and Lu, 2004) , E2F/DP1 (Martin et al., 1995) and p73a transcription factor (Zeng et al., 1999) . These interactions suggest that MDM2 has p53-independent functions (Ganguli and Wasylyk, 2003) . In particular, the interaction with both E2F1 and DP1 proteins stimulates transcription of E2F-target genes involved in cell cycle progression (Martin et al., 1995) , whereas it can also antagonize E2F1-mediated apoptosis in p53À/À cells (Loughran and La Thangue, 2000) .
It is well established that E2F1 interacts with pRb to regulate the G1/S phase transition. Overexpression of E2F1 promotes cell growth and is sufficient to drive quiescent cells into S phase (Johnson et al., 1993) . However, E2F1À/À knockout mice develop a broad spectrum of tumors, suggesting that E2F1 also functions as a tumor suppressor. Indeed, several authors reported that E2F1 can induce apoptosis through p53-dependent (Kowalik et al., 1995; Qin et al, 1994; Wu and Levine, 1994) and p53-independent mechanisms (Irwin et al., 2000) , by upregulating apoptotic genes like Apaf-1 (Furukawa et al., 2002) , p73 (Stiewe and Putzer, 2000) , caspase 3 and 7 (Muller et al., 2001) , Noxa and PUMA (Hershko and Ginsberg, 2004) . Furthermore, forced expression of E2F1 caused increased sensitivity to DNA-damaging agents and topoisomerase II inhibition in a p53-independent manner (Nip et al., 1997) . Interestingly, MDM2 can downregulate the levels of E2F1 and DP1 subunits by inducing degradation of the heterodimer (Loughran and La Thangue, 2000) .
We have hypothesized that binding of Nutlin-3a to MDM2 may interfere with E2F1 regulation and could affect the response of cancer cells to chemotherapy. Here, we show that in p53 mutant cells, Nutlin-3a inhibits E2F1's interaction with MDM2 and increases E2F1 transcriptional activity following DNA damage. Furthermore, chemotherapy-induced apoptosis is enhanced by Nutlin-3a in an E2F1-dependent manner likely through upregulation of p73a and Noxa in cells lacking a functional p53 pathway.
Results

Nutlin-3a induces apoptosis in p53wt cells and enhances chemotherapy-induced apoptosis in cells with mutant p53
We investigated the effect of Nutlin-3a when combined with chemotherapy in soft tissue-sarcoma cell lines that differ in their p53 status, the dedifferentiated liposarcoma cell line LS141 (wild-type p53) and the peripheral nerve sheath tumor cell line MPNST (mutant p53). Nutlin-3a and cisplatin (Cis) were administered individually, sequentially (Cis-ND and Cis-Nut) or concurrently (Nut þ Cis) for 48 h. Cells were then tested for induction of apoptosis by Annexin-V þ labeling. In p53wt LS141 cells, 5 mM Nutlin-3a induced 3270.5% apoptosis, which was not affected by co-treatments with Cis ( Figure 1a ). However, in MPNST cells, Nutlin-3a alone was no different than untreated cells, whereas the concurrent treatment of Cis with Nutlin-3a resulted in 28.470.6% Annexin-V-positive cells (Figure 1b) . Also, the sequential treatment of MPNST cells resulted in 34.870.9% apoptotic cells, which was significantly greater than any other condition tested (Po0.001).
Nutlin-3a enhances cytotoxicity of genotoxic agents in p53 mutant cells We further investigated the effect of combination therapy on MPNST cells by proliferation assays. The IC 50 for Cis alone was 771.7 mM, which decreased to 4.270.5 and 1.470.7 mM after addition of 5 and 10 mM Nutlin-3a, respectively. To exclude non-MDM2-mediated effects, we used the inactive enantiomer Nutlin-3b (Vassilev et al., 2004) , and the IC 50 was not different than Cis alone (data not shown). To assess the validity of these observations with other cell lines, we used a panel of p53-mutant or p53-null cells, and different DNA damaging agents. A series of colon (HT29 and SW480), lung (H1299) and prostate (DU145 and PC3) cancer cell lines were assayed to evaluate the inhibitory effect on cell growth induced by carboplatin and doxorubicin, either alone or in combination with 5 and 10 mM Nutlin-3a. The dose-response curves are shown in Figure 2a and the IC 50 from this data are summarized in Figure 2b . Except for minimal activity against DU145 (IC 50 , 22 mM), Nutlin-3a was essentially inactive in all the cell lines tested with IC 50 >30 mM. As single agents, carboplatin and doxorubicin showed activity in all cell lines that was further enhanced by Nutlin-3a. With the addition of 10 mM Nutlin-3a, the IC 50 To determine whether these observations could be extended to other DNA damaging agents in apoptosis assays, we treated the prostate p53-mutant cell line DU145 with a series of chemotherapeutic drugs, including gemcitabine and SN-38 (the active metabolite of irinotecan), as well as Cis, in combination with Nutlin3a. As shown in Figure 2c , Nutlin-3a increased gemcitabine, SN-38 and Cis-induced apoptosis two-to threefold when compared to either agent alone. We next elected to evaluate the inhibitory effect of combination therapy by clonogenic assay in DU145 cells treated with increasing concentrations of Nutlin-3a alone or in combination with 1 mM Cis. Concurrent drug exposure resulted in a dose-dependent loss of clonogenic survival by Nutlin-3a ( Figure 2d ).
Nutlin-3a affects E2F1 protein levels in a p53/MDM2-dependent manner The Nutlins were engineered to specifically interfere with the p53-MDM2 binding, resulting in the accumulation of free and stable p53 protein. The effects of Nutlin3a in cell lines with wild-type p53 have been well Nutlin-3a enhances E2F1-induced apoptosis G Ambrosini et al characterized (Carvajal et al., 2005) . However, there is no mechanistic evidence of Nutlin-3a-mediated effects in p53 mutant cells. Thus, we treated both the sarcoma cell lines with single agents or in combination and tested the expression of proteins that reportedly bind to MDM2 by immunoblotting. As shown in Figure 3a , in LS141 cells with p53wt Nutlin-3a induced an increase in MDM2, p53 and p21 expression. This is consistent with the stabilization of p53 and the feedback upregulation of MDM2. Most surprisingly, in the LS141 cells, E2F1 and pRb protein levels were downregulated by Nutlin-3a with or without Cis. In contrast, MPNST cells with a defective p53 pathway, showed no upregulation of p53 or p21. MDM2 levels appeared to decrease with Cis therapy but less so when combined with Nutlin-3a. Furthermore, in marked contrast to the p53wt LS141 cells, Nutlin-3a did not suppress the expression of either E2F1 or pRb as a single agent or when combined with Cis.
As LS141 cells have an amplified MDM2 gene, which could alter the interpretation of these results, we validated the effects of combination treatments in HCT116 cells with wild-type p53 (HCTp53 þ / þ ) and its p53 null (HCTp53À/À) isogenic subcell line (Figure 3b ). In the HCTp53 þ / þ cells, Nutlin-3a had similar effects on E2F1 and pRb as in the p53wt LS141 cell line, with induction of p53, MDM2 and p21, and suppression of E2F1 and Rb, both with Nutlin-3a alone and with Cis therapy. In contrast, in the HCTp53À/À cells there was no induction of p53 or p21 and the changes in MDM2 are comparable to the p53mut MPNST cells. Again in the HCTp53À/À cells, Nutlin-3a did not suppress E2F1 or pRb as either a single agent or in combination with Cis. In addition, these cells also underwent apoptosis with the combination treatment that was greater than either drug alone (data not shown).
Nutlin-3a inhibits E2F1 binding to MDM2 and increases E2F1 transcriptional activity in the presence of Cis These results confirm that Nutlin-3a's effects are mediated by p53 in cells with a functional p53 pathway. In p53mut cells, the enhancement of chemotherapyinduced apoptosis by Nutlin-3a appears to be mediated by other MDM2 binding target proteins. As E2F1's role in chemotherapy-induced apoptosis has been well characterized (Banerjee et al., 1998; Meng et al., 1999) , we further explored the effects of Nutlin-3a on E2F1. We examined whether Nutlin-3a could affect the stability of E2F1 by inhibiting MDM2-mediated ubiquitination. Immunoprecipitation of E2F1 from Nutlin-3a-treated MPNST cells followed by immunoblotting with a ubiquitin antibody produced a ladder of slowly migrating ubiquitinated forms that decreased in a dose-dependent manner, although the levels of immunoprecipitated E2F1 were comparable ( Figure 4A, a) . Nutlin-3a also induced a time-dependent increase in E2F1 protein with a peak of induction at 24-36 h ( Figure 4A, b) . In contrast, ubiquitination of E2F1 in LS141 increased with Nutlin-3a ( Figure 4B, d) , and induced a time-dependent decrease in E2F1 ( Figure 4B , e). The proteasome inhibitor PS341 prevented the downregulation of E2F1 when combined with Nutlin3a for 24 h. This would suggest that in p53wt cells the degradation of E2F1 is proteasome dependent.
To further explore the role of MDM2 in E2F1 regulation, p53wt and p53mut cells were transfected with control or MDM2-specific SMARTpool small interfering RNA (siRNA) for 48 h and were treated with or without Nutlin-3a for the last 24 h of transfection. In p53mut cells, depletion of MDM2 induced an increase in E2F1 protein expression, as compared to control siRNA ( Figure 4A, c) . With Nutlin-3a treatment, E2F1 was induced in both siRNA control cells and in MDM2-specific siRNA-transfected cells ( Figure  4A, c) . On the contrary, in p53wt cells E2F1 decreased with MDM2 downregulation as compared to siRNA controls both in the absence and presence of Nutlin-3a ( Figure 4B, f) . In addition, p53 was induced with the suppression of MDM2, even in cells that were not treated with Nutlin-3a ( Figure 4B, f) .
A previous report demonstrated a direct association of MDM2 with a region of E2F1 that shares a substantial similarity with the MDM2-binding domain of p53 (Martin et al., 1995) . To test whether Nutlin-3a could block the association of E2F1 with MDM2 in p53mut cells, MPNST lysates were precipitated with an E2F1 antibody and probed for MDM2. In untreated Figure 3 Nutlin-3a modulates MDM2-binding proteins in a p53-dependent manner. (a) LS141 and MPNST were analysed for various protein expression after exposure to drug-free media (ND) or 5 mM Nutlin-3a and Cis combinations, using anti-p53, -MDM2, -E2F1, -pRb, -p21 and -tubulin antibodies. (b) Wild-type and p53-null HCT116 cells were treated with 5 mM Nutlin-3a and Cis, and analysed as above.
Nutlin-3a enhances E2F1-induced apoptosis G Ambrosini et al cells, MDM2 co-immunoprecipitated with E2F1 (Figure 5a ), whereas treatment with Nutlin-3a for 24 h resulted in loss of binding, both in the presence or absence of Cis (Figure 5a ). E2F1 also co-immunoprecipitated pRb in control or Nutlin-3a-treated cells, whereas Cis decreased E2F1 binding to pRb, especially in the presence of Nutlin-3a. Whole-cell lysates were immunoblotted for MDM2, pRb and E2F1 as loading controls. This data would indicate that there is an increase in free E2F1 protein following both Nutlin-3a and combination therapy with Cis. It has been shown that DNA damage induces E2F1 stabilization and E2F1-mediated apoptosis (Lin et al., 2001) . This, in conjunction with the increase in free E2F1, prompted us to test whether Nutlin-3a could enhance the transcriptional activity of E2F1 in the presence of Cis. MPNST cells were transfected with an E2F1 luciferase reporter plasmid. Then, cells were treated with Nutlin-3a or Cis for 24 h, followed by Nutlin-3a or drug-free (ND) media for 4, 8, 12 and 16 h. At all time points tested, Nutlin-3a alone did not induce E2F1 activity. Cis alone induced a slight effect starting at 4 h. However, there was a time-dependent increase in E2F1 activity with Cis->Nut treatment, that was 2.7-fold greater than Cis alone (Cis->ND, Po0.02) at 12 h post-treatment (Figure 5b ). These results would indicate that though Nutlin-3a can promote a decrease in E2F1 binding to both MDM2 and pRb, the transcriptional activation of free E2F1 requires concomitant chemotherapy-induced DNA damage.
E2F1 mediates the enhancement of apoptosis by Nutlin-3a after DNA damage To confirm that E2F1 plays a role in the enhancement of Cis-induced apoptosis by Nutlin-3a in p53mut cells, MPNST cells were transiently transfected with plasmids expressing wild-type E2F1, or the dominant-negative DE2F1(1-363), which binds to DNA but is incapable of transactivating target genes. The cells were treated as above, and tested for apoptosis by quantitative fluorescence microscopy (QFM) (Figure 6a ). Consistent with our previous data, MPNST cells expressing the control vector (pCMV) showed the greatest enhancement of apoptosis with the Cis and Nutlin-3a combination, when compared to single agent Cis therapy. In the cells transfected with wild-type E2F1 (E2F1-WT), apoptosis increased to 12.271.6% with Cis->ND and to 23.572.1% with combination treatment. In contrast, cells expressing the dominant-negative DE2F1(1-363) had significantly reduced levels of apoptosis under identical treatment conditions, even when compared to the vector-transfected cells (Po0.04). In addition, MPNST cells were transfected with E2F1 or control Figure 4 Nutlin-3a regulates E2F1 in a p53-dependent manner. (A) MPNST and (B) LS141 were treated with 5 and 10 mM Nutlin-3a for 24 h. Immunoprecipitates (IP) with a polyclonal anti-E2F1 antibody were analysed by immunoblotting using ubiquitin and E2F1 antibodies (a and d). Cells were treated with 5 mM Nutlin-3a for the indicated times and examined for E2F1 expression (b and e). Bands were quantified by densitometry, normalized to tubulin and expressed as fold-increase over untreated cells (b). LS141 were also treated with 20 nM proteasome inhibitor PS431 for 24 h (e). Cells were transfected with SMARTpool MDM2 or control siRNA for 48 h and treated with Nutlin-3a for 24 h before immunoblotting (c and f).
siRNA (Figure 6b , inlet) and incubated with Cis with or without 5 mM Nutlin-3a. Downregulation of E2F1 significantly decreased the level of apoptosis in MPNST cells by 2.5-fold (Figure 6b ).
E2F1-mediated induction of apoptosis involves transcriptional activation of proapoptotic genes. Several reports have shown that DNA damage results in E2F1-mediated transcription of p73a, a p53 homolog involved in the activation of p53-responsive target genes and apoptosis (Irwin et al., 2000) . As shown in Figure 6c , the sequential treatment of Cis-Nut induced a timedependent increase in p73a, whereas the treatment with Cis alone induced a slight increase above baseline. Noxa, a proapoptotic protein that can be transcriptionally induced by E2F1 (Hershko and Ginsberg, 2004) was also upregulated by Cis-Nut therapy when compared to Cis alone (Figure 6c ). Nutlin-3a alone had no effect under these treatment conditions (data not shown). Furthermore, the induction of these genes was abrogated in cells expressing the dominant-negative DE2F1(1-363) (Figure 6d ). Interestingly, in cells transfected with wild-type E2F1, Cis treatment alone induces both p73a and Noxa expression. This is consistent with our results indicating that these transfected cells are more sensitive to Cis alone, but not to the levels observed with Cis and Nutlin-3a combination (Figure 6a) . Collectively, these results indicate that in p53mut cells, inhibition of MDM2 by Nutlin-3a enhances chemotherapy-induced apoptosis by inducing free E2F1, which activates transcription of proapoptotic proteins.
Discussion
Nutlins are selective small-molecule inhibitors of the p53-MDM2 interaction that stabilize p53 and activate the p53 pathway. In tumor cells with wild-type p53, this results in induction of p53 target genes, cell cycle arrest and apoptosis (Vassilev et al., 2004) . In some cases, growth arrest at the G1 and G2 phases of the cell cycle by Nutlin-3a can protect proliferating cells from the cytotoxic effect of mitotic poisons (Carvajal et al., 2005) . Previous findings have suggested that Nutlins may offer a new therapeutic option to patients with tumors that express wild-type p53 either as single agent (Vassilev, 2005; Tovar et al., 2005) or as combination therapy (Kojima et al., 2005; Stuhmer et al., 2005) . In contrast, tumor cells with mutant p53 are resistant to Nutlin-3a (Carvajal et al., 2005) . This would indicate that therapeutic utility of MDM2 antagonists is limited to the treatment of tumors that are wild type for p53.
However, p53 is mutated in approximately 50% of all malignancies, and this correlates with lack of response to conventional anticancer therapies. It is known that MDM2 binds not only to p53 but also to a series of other binding partners including E2F1 (Martin et al., 1995) . E2F1 can trigger apoptosis in a manner that is both dependent and independent of p53. In this study, we show that in tumor cells lacking a functional p53, Nutlin-3a enhances cytotoxicity of genotoxic agents via E2F1 stabilization and activation. In these cells, Nutlin3a inhibits the binding of MDM2 to E2F1, and in the presence of DNA damage the free E2F1 induces proapoptotic molecules, such as p73a and Noxa. A negative regulation of MDM2 on E2F1 was first reported in an article by Loughran and co-workers, where they showed that MDM2 promotes E2F1 degradation and antagonizes the apoptotic properties of E2F1 (Loughran and La Thangue, 2000) . However, in p53wt cells (LS141 and HCTp53 þ / þ ) the proapoptotic activity of Nutlin-3a seems to be exclusively via p53, as E2F1 is completely downregulated. The loss of E2F1 expression seems to be mediated by increased ubiquitination and subsequent proteasomal degradation. In these cells, E2F1 is downregulated after inhibition of MDM2 by Nutlin-3a treatment or by depletion of MDM2 by siRNA. In both cases, p53 is highly induced and showed a negative correlation with E2F1 expression. The p53 dependence for the interaction between E2F1 and MDM2 was first suggested by Wasylyk et al. (1999) . This group showed that IP3, a peptide with a sequence resemblance to p53 but with a 100-fold greater affinity for MDM2, induced a decrease Figure 5 Nutlin-3a inhibits binding of E2F1 to MDM2 and increases E2F1 activity after DNA damage in p53 mutant cells. (a) Untreated MPNST cells (À) or treated with 5 mM Nutlin-3a and Cis ( þ ) for 24 h and were immunoprecipitated with an anti-E2F1 antibody. Immunocomplexes were subjected to immunoblotting with anti-MDM2, -pRb and -E2F1 antibodies. Equal amounts of whole-cell lysates were blotted with the same antibodies to demonstrate equal loading. (b) MPNST were transiently transfected with E2F1(3)-Luc reporter vector in 24-well plates. One day later, cells were treated with 5 mM Nutlin-3a (white bars) or 5 mM cisplatin for 24 h followed either by drug-free (dashed bars) or by 5 mM Nutlin-3a containing media (black bars) for the indicated times. Luciferase activity was normalized to Renilla luciferase activity for transfection efficiency and expressed as fold induction compared to untreated cells (0 time, value set at 1). Data are representative of three independent experiments; bars, 7s.d.
Nutlin-3a enhances E2F1-induced apoptosis
G Ambrosini et al in E2F1 activity in p53wt SA1 osteosarcoma cells and MCF-7 breast cancer cells. SA1 cells transfected with E6 to inhibit p53 showed a slight increase in E2F1 activity and overcame the IP3-induced inhibition of E2F1. Nutlin-3a can displace both p53 and E2F1 from MDM2, and we can assume that they bind to the same MDM2-binding pocket. However, the affinity of each protein to MDM2 is not known, and it is plausible that the presence of p53 may affect the stability of E2F1.
Other mechanisms are also involved in E2F1 stability, such as degradation by SCF SKP2 E3 ligase, which is antagonized by MDM2 (Zhang et al., 2005) . Further studies are needed to elucidate the role that p53/MDM2 plays in the regulation of E2F1.
Our results also indicate that the induction of apoptosis by Nutlin-3a in cells without functional p53 requires pre-existing (or concomitant) DNA damage, caused by genotoxic drugs (e.g. Cis, doxorubicin). This effect is E2F1 dependent, as transfection of MPNST cells with E2F1-siRNA or a dominant-negative E2F1 construct prevents the potentiation of Cis-induced apoptosis by Nutlin-3a, whereas the overexpression of wild-type E2F1 further promotes this effect. Coexisting DNA damage appears to be necessary for Nutlininduced E2F1 activation of proapoptotic genes. DNA damage itself leads to a specific induction of E2F1 accumulation, dependent on the phosphorylation by ataxia-telangiectasia mutated (ATM) kinase activity and the related kinase ATR (ATM and Rad3-related kinase) (Lin et al., 2001) . Also, Pediconi et al. (2003) demonstrated that E2F1 is acetylated in response to DNA damage and this modification is required to target E2F1 to the promoters of proapoptotic target genes such as p73a. The stabilization of E2F1 in response to genotoxic stress is well established and it plays an important role in the increased sensitivity to chemotherapy. Unscheduled upregulation of E2F1 activity in cells arrested in S phase following a genotoxic stress induces apoptosis (Huang et al., 1997; Nip et al., 1997; Meng et al., 1999) . Consistent with these results, cell cycle analysis of MPNST cells revealed that the S-phase population increased from 27% of untreated controls to 60% with Cis alone, and 86% with Cis-Nut treatment (data not shown).
In conclusion, our studies indicate that the enhancement of chemotherapy-induced apoptosis by Nutlin-3a in cells with dysfunctional p53 is mediated by E2F1 likely through transcriptional activation of p73a and Noxa, in the setting of coexisting DNA damage. Thus, the use of small-molecule inhibitors of MDM2 may have clinical utility in the treatment of patients with mutant p53 tumors when combined with genotoxic agents.
Materials and methods
Cell culture and drug treatments MPNST cells were kindly provided by Dr Jonathan Fletcher (DFCI, Boston, MA, USA). LS141 primary human cell line was derived from a patient with high grade retroperitoneal dedifferentiated liposarcoma. HT29, SW480, DU145, PC3, H1299 cells were purchased from American Type Culture Collection. HCT116 human colon carcinoma cells and its p53-null variant were a gift from Dr Vogelstein (J Hopkins University, Baltimore, MA, USA). Cells were grown in Dulbecco's modified Eagle's medium (SW480), or McCoy's 5A (HT-29, HCT116), or Roswell Park Memorial Institute-1640 medium (MPNST, LS141, DU145, PC3 and H1299), supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. The selective small-molecule antagonist of MDM2, Nutlin-3a was prepared as stock solution of 10 mM in dimethyl sulfoxide (DMSO) and stored at À201C. Drug treatments were carried out as single agents or in combinations for 48 h. In sequential therapy, cells were exposed to each drug for 24 h.
Immunoprecipitation and immunoblotting
Cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Tween 20, 0.5 mM ethylenediaminetetraacetic acid, 1 mM NaVO 3 , 10% glycerol and protease inhibitor cocktail tablets (Roche Biochemicals, Indianapolis, IN, USA). Equivalent amount of proteins were incubated with a polyclonal E2F1 antibody (Abcam, Cambridge, MA, USA) for 3 h at 41C. Then, 25 ml of agarose beads (Upstate Biotechnology, Lake Placid, NY, USA) were added for an additional hour. Immunocomplexes were washed three times, loaded on 4-12% polyacrylamide gel electrophoresis gels (Invitrogen, Carlsbad, CA, USA) and detected by immunoblotting with antibodies specific for MDM2, E2F-1, p53, p21, (Santa Cruz Biotechnology, Santa Cruz, CA, USA), pRb (BD Pharmingen, San Diego, CA, USA) and tubulin (Upstate Biotechnology).
Proliferation assay
Cellular viability was evaluated by 3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay as described (Carvajal et al., 2005) . Briefly, eight cell types were seeded in 96-well plates at a density of 5 Â 10 3 cells/well in 100 ml of medium for 24 h. Drug dilutions were made in medium at twofold increments to the final concentrations of 2.5, 5, 10 and 20 mM. At day 5, 20 ml of MTT reagent was added to each well and incubated for 2 h at 371C, and absorption was read at dual wavelength (520/650 nm) using a multi-channel plate reader (SpectraMax 340pc, Molecular Devices Corporation, Sunnyvale, CA, USA). Triplicate wells were assayed for each condition and percentage inhibition was calculated for each cell line.
Apoptosis assays
Evaluation of apoptosis was carried out using the Guava NexinTM Kit (Guava Technologies, Hayward, CA, USA) following the manufacturer's instructions. Both adherent and floating cells were counted using the Guava PCA (Guava Technologies). The measurement of apoptosis by QFM was carried out using 4 0 ,6 0 -diamidino-2-phenylindole (DAPI, Sigma, St Louis, MO, USA) staining of nuclear chromatin. Cells were scored for the incidence of apoptotic chromatin condensation using a Nikon Eclipse TE2000-U microscope (Nikon, Nikon Instruments Inc., Melville, NY, USA). The statistical significance of the experimental results was determined by the two-sided t-test.
Clonogenic assay
Cells were plated in triplicate onto 100-mm dishes at 1000 cells/ dish and were allowed to attach for 24 h before treatment. Then, cells were cultured in drug-free medium for 10-12 days. The resulting colonies were scored after staining with 0.01% crystal violet (Sigma).
Plasmids and transfections pRcCMV (vector control), pRcCMV-E2F1 (full-length E2F-1), and pRcCMV-E2F1-(1-363) (truncated E2F1 encoding 363 amino acids and lacking the COOH-terminal 74 amino acids) were generously provided by Dr David M Livingston (DFCI, Boston, MA, USA). Cells were incubated with transfection mixture containing 3 ml of FuGENE 6 (Roche) and 3 mg of E2F1 plasmids. Drug-free or drug-containing media was added to the cells 24 h after transfection. For luciferase assays, cells were transfected with 0.25 mg of TransLucent E2F1(3 Â ) reporter vector (Panomics, Redwood City, CA, USA) and 1:10 ratio of Renilla control vector to normalize for variations in transfection efficiency. Cell extracts were analysed for luciferase activity using the Dual Luciferase Reporter Assay (Promega, Madison, WI, USA). SiRNAs against E2F1, MDM2 (SMARTpool) and nonspecific control siRNA were purchased from Dharmacon Inc. (Lafayette, CO, USA). Cells were transfected using Oligofectamine reagent (Invitrogen) following the manufacturer's instructions.
